GSK Buys Liver Drug for Up to $2 Billion to Boost Pipeline (3)

GSK Plc agreed to buy an experimental medicine for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies.

The treatment is ready to enter the last stage of clinical tests, the UK drugmaker said Wednesday. The medicine could become a blockbuster, according to analysts, and the deal may help alleviate concern about GSK’s growth prospects as some of its top medicines age.

An Eli Lilly & Co. Zepbound injection pen.

Photographer: Shelby Knowles/Bloomberg

Liver disease is attracting growing interest from drugmakers, including obesity leaders Eli Lilly & Co. and Novo Nordisk A/S, as there are few ...